Mean perceived breast cancer risk at baseline and at the laboratory and 6-month follow-up by experimental groupa
| Experimental group | Gail Score (lifetime) | Time of assessment | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Point estimate given | Range estimates given | Baseline | Follow-up | 6-month follow-up | ||||||
| Absolute risk (numerical 0–100) | ||||||||||
| No | No | 6.96 (3.84) | 31.6 (25.9) | 32.1 (26.1) | 37.2 (22.7) | |||||
| No | Yes | 7.60 (4.64) | 36.7 (22.5) | 21.9 (19.3) | 30.7 (23.6) | |||||
| Yes | No | 7.95 (5.07) | 39.5 (24.5) | 24.2 (22.1) | 34.7 (24.2) | |||||
| Yes | Yes | 8.57 (6.00) | 39.2 (22.5) | 16.6 (17.5) | 36.2 (21.2) | |||||
| Point estimate provided (collapsing across range condition)b | ||||||||||
| No | 7.28 (4.24) | 34.3 (24.1) | 27.2 (23.5) | 33.8 (23.3) | ||||||
| Yes | 8.27 (5.52) | 39.2 (23.5) | 20.2 (19.9) | 35.4 (22.6) | ||||||
| Range provided (collapsing across point condition)c | ||||||||||
| No | 7.46 (4.50) | 35.8 (25.2) | 27.8 (24.3) | 36.0 (23.3) | ||||||
| Yes | 8.10 (5.53) | 37.8 (22.5) | 19.4 (18.6) | 33.3 (22.6) | ||||||
a Numbers in parentheses represent SD. The means for the baseline and laboratory follow-up are based on a sample size of 169; means for the 6-month follow-up are based on 151 women.
b Significant pre-post by point estimate interaction [F(1164) = 19.36, P < 0.0001] comparing baseline and the laboratory follow-up.
c Significant pre-post by range interaction [F(1164) = 18.01, P < 0.0001] comparing baseline and the laboratory follow-up.